Arti Bhan

Nov 14, 2024 | healio.com | Michael Monostra |Richard Smith |Arti Bhan

Arti Bhan, MD, FACE Hypothyroidism affects 3% to 7% of the U.S. population, making it a common endocrine disorder primarily treated with levothyroxine. Despite biochemical control, 5% to 10% of patients report persistent symptoms such as mood disturbances, fatigue and "brain fog." The etiology of this is poorly understood and is believed to be multifactorial.

Apr 10, 2024 | healio.com | Michael Monostra |Richard Smith |Arti Bhan

Arti Bhan, MD, FACE Primary hyperparathyroidism is the most common cause of hypercalcemia in outpatient settings. Low bone mineral density is an indication for parathyroid surgery, as improvement in BMD after surgery is well documented. Patient and biochemical characteristics that predict improvement in BMD, and thereby fracture risk, are not well elucidated.

Mar 15, 2024 | healio.com | Michael Monostra |Richard Smith |Arti Bhan

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Adults who undergo a total thyroidectomy due to cancer have an increased all-cause mortality risk. No increased mortality risk was seen for adults who have a thyroidectomy to treat goiter or thyrotoxicosis.

Jun 26, 2023 | opmed.doximity.com | Catherine Anastasopoulou |Arti Bhan |Connie Newman |Lipid metabolism

Op-Med is a collection of original articles contributed by Doximity members. Another great meeting from the Endocrine Society is complete. A variety of presentations were available, and each participant had to choose their favorites, but here are my personal highlights from the lectures that I attended.

Jun 26, 2023 | opmed.doximity.com | Connie Newman |Arti Bhan |Ann Beach |Lipid metabolism

Op-Med is a collection of original articles contributed by Doximity members. The possibility that testosterone replacement for men with hypogonadism increases cardiovascular risk has been a controversial topic, and the data are inconsistent. Many studies have been retrospective, and the few randomized trials were not designed to evaluate cardiovascular outcomes and were underpowered.